Compare PHAR & AOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAR | AOD |
|---|---|---|
| Founded | 1988 | N/A |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 998.4M |
| IPO Year | 2020 | 2006 |
| Metric | PHAR | AOD |
|---|---|---|
| Price | $15.46 | $9.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $39.00 | N/A |
| AVG Volume (30 Days) | 20.2K | ★ 675.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.50 | $7.65 |
| 52 Week High | $21.34 | $10.77 |
| Indicator | PHAR | AOD |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 40.94 |
| Support Level | $12.98 | $9.57 |
| Resistance Level | $17.29 | $10.10 |
| Average True Range (ATR) | 0.66 | 0.18 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 29.43 | 28.03 |
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.